{@shortdesc}

{@title}
{@headline}
Slide: {@currentrow} of {ds_RowCount}  PreviousStopPlayNext

The Drug Safety Executive Council (DSEC) is a peer-to-peer membership of over 1,600 drug safety leaders with the common objective of advancing the development of better and safer medicines.  Learn More.

DSEC is driven by an esteemed Advisory Board of industry executives representing many of the largest and most prominent biopharmaceutical companies in the world.  Regular membership is complimentary and limited to current employees of companies developing small and large molecule pharmaceuticals.
Why Join DSEC?

Regular membership is complimentary
Engage in member-driven discussions, research, and presentations that will help you lead your organization to better decision making
Network with other high-level executives at leading biopharmaceutical companies to drive change that will encourage business growth
Membership is limited to leaders representing companies who develop small and large molecule pharmaceuticals

 
 
Featured Events & Content

Second Annual DSEC Member Retreat - Special hotel package!
Register by July 24th and DSEC will include 2 nights hotel with your registration. Retreat is August 25-26, 2009. Royal Sonesta, Cambridge, MA. More information...
On-Demand Webinar: A Groundbreaking Collaboration
Cooperatively Evaluating Safety Technology on an Ongoing Basis - originally presented June 30th, 2009 - Open to members and non-members.
NEW PLATINUM MEMBERSHIP OPTION
Learn more about our Platinum Membership option.
Annual POST APPROVAL DRUG SAFETY Conference featuring Jack Reynolds
November 4-6, 2009 at Crown Plaza Philadelphia Center City. Special Discount for DSEC members.
The Impact of Collaboration when Evaluating New Technologies
Brief two page case study on the power of collaboration in non-clinical drug safety,
DSEC in the News!
There was a recent article entitled: DSEC Recruits Pharmas For Early Drug Safety Testing published in Bio-IT World. See full article by clicking on title.

On-Demand Web Sessions

MAY WEBINAR: De-Risking Drug Candidates in Early Clinical Development
Originally May 7th, 2009, 11:00 AM - 12:00PM (15:00 GMT) Watch Archived version here
MARCH WEBINAR: Biosimilars: What is the Non-Clinical Component to Biosimilar Registry Dossiers?
Originally held March 25, 2009 at 11:00 AM ET (15:00 GMT). View slides and on-demand version of the event here.
The Adoption Process of Novel Technologies in Preclinical R&D
Held on November 5, 2008
Seizing the Opportunities for Government Partnerships to Improve Drug Safety
Featuring Dr. Janet Woodcock, Deputy Commissioner and Chief Medical Officer, FDA. Held July 26, 2007

Executive Summaries: Benchmarking Studies/Reports

Executive Summary: Confronting Major Safety Issues of the 21st Century
Executive Summary from the Inaugural DSEC Member Summit
The Emergence of High-Content Screening as a Tool for Safety Assessment
Drug safety challenges rank as the leading cause of attrition of compounds in clinical development